BR0108143A - Derivados heteroaromáticos de carboxamida e seu uso como inibidores da enzima ikk-2 - Google Patents

Derivados heteroaromáticos de carboxamida e seu uso como inibidores da enzima ikk-2

Info

Publication number
BR0108143A
BR0108143A BR0108143-8A BR0108143A BR0108143A BR 0108143 A BR0108143 A BR 0108143A BR 0108143 A BR0108143 A BR 0108143A BR 0108143 A BR0108143 A BR 0108143A
Authority
BR
Brazil
Prior art keywords
ikk
carboxamide
inhibitors
enzyme
heteroaromatic derivatives
Prior art date
Application number
BR0108143-8A
Other languages
English (en)
Inventor
Baxter
Andrew
Brough
Stephen
Faull
Alan
Johnstone
Craig
Mcinally
Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0108143A publication Critical patent/BR0108143A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS HETEROAROMáTICOS DE CARBOXAMIDA E SEU USO COMO INIBIDORES DA ENZIMA IKK-2". A presente invenção se refere a compostos de carboxamida heteroaromáticos de fórmula (I): em que A, R^ 1^, R^ 2^ e X são como definidos no relatório descritivo, a processos e intermediários usados na sua preparação, a composições farmacêuticas contendo os mesmos e ao seu uso em terapias.
BR0108143-8A 2000-02-12 2001-02-07 Derivados heteroaromáticos de carboxamida e seu uso como inibidores da enzima ikk-2 BR0108143A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003154.2A GB0003154D0 (en) 2000-02-12 2000-02-12 Novel compounds
PCT/SE2001/000248 WO2001058890A1 (en) 2000-02-12 2001-02-07 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2

Publications (1)

Publication Number Publication Date
BR0108143A true BR0108143A (pt) 2003-01-21

Family

ID=9885396

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108143-8A BR0108143A (pt) 2000-02-12 2001-02-07 Derivados heteroaromáticos de carboxamida e seu uso como inibidores da enzima ikk-2

Country Status (21)

Country Link
US (2) US7358376B2 (pt)
EP (1) EP1261600B1 (pt)
JP (1) JP4812999B2 (pt)
KR (1) KR100738165B1 (pt)
CN (1) CN1243747C (pt)
AT (1) ATE266019T1 (pt)
AU (1) AU781047B2 (pt)
BR (1) BR0108143A (pt)
CA (1) CA2396824C (pt)
DE (1) DE60103132T2 (pt)
DK (1) DK1261600T3 (pt)
ES (1) ES2218376T3 (pt)
GB (1) GB0003154D0 (pt)
IL (2) IL150482A0 (pt)
MX (1) MXPA02007734A (pt)
NO (1) NO327741B1 (pt)
NZ (1) NZ519947A (pt)
PT (1) PT1261600E (pt)
TR (1) TR200401962T4 (pt)
WO (1) WO2001058890A1 (pt)
ZA (1) ZA200205300B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
JP2004523476A (ja) * 2000-10-12 2004-08-05 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
US6846834B2 (en) 2000-10-26 2005-01-25 Amgen Inc. Antiinflammation agents
HUP0304045A3 (en) * 2001-02-01 2005-05-30 Bristol Myers Squibb Company P Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
AP1753A (en) * 2001-06-11 2007-07-18 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavvivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
CA2460942A1 (en) 2001-09-19 2003-03-27 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
JP2005504806A (ja) * 2001-09-21 2005-02-17 スミスクライン・ビーチャム・コーポレイション 化合物
JP2006515828A (ja) 2001-09-27 2006-06-08 スミスクライン・ビーチャム・コーポレイション 化学化合物
WO2003028731A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029242A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation NF-λB INHIBITORS
EP1444010A2 (en) * 2001-10-30 2004-08-11 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
EP1513516B1 (en) 2002-06-06 2008-12-03 Boehringer Ingelheim Pharmaceuticals Inc. SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
US7179836B2 (en) 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
JP2006510676A (ja) * 2002-12-06 2006-03-30 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
KR101058696B1 (ko) * 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
RU2006107782A (ru) 2003-08-15 2006-08-10 Астразенека Аб (Se) Замещенные тиофены и их применение
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1678164B1 (en) * 2003-10-14 2007-04-11 Pharmacia Corporation Substituted pyrazinone compounds for the treatment of inflammation
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0509795A (pt) * 2004-04-12 2007-10-23 Sankyo Co composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
WO2006036031A1 (ja) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited 縮合フラン誘導体およびその用途
EP1876179B1 (en) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AU2006266028B2 (en) 2005-06-30 2012-03-15 Smithkline Beecham Corporation Chemical compounds
JP2009539865A (ja) 2006-06-06 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用
EA201101492A1 (ru) * 2006-11-15 2012-09-28 Вирокем Фарма Инк. Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
EP2119703B1 (en) 2007-01-15 2012-12-12 Santen Pharmaceutical Co., Ltd Novel indole derivative having inhibitory activity on i b kinase
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8445529B2 (en) 2008-07-14 2013-05-21 Santen Pharmaceutical Co., Ltd. Indole derivative having, carbamoyl group, ureido group and substituted oxy group
KR20110044767A (ko) 2008-08-25 2011-04-29 산텐 세이야꾸 가부시키가이샤 우레이도기, 아미노카르보닐기 및 치환기를 가져도 좋은 2환식기를 치환기로서 갖는 신규 피롤 유도체
JP2010077119A (ja) * 2008-08-25 2010-04-08 Santen Pharmaceut Co Ltd ウレイド基、アミノカルボニル基及び置換フェニル基を置換基として有するピロール誘導体を有効成分として含有する骨・関節疾患の予防又は治療剤
MY150568A (en) * 2008-11-14 2014-01-30 Du Pont Method for preparing a non-hydratable crystal form
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2012046793A1 (ja) * 2010-10-07 2012-04-12 参天製薬株式会社 ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP2634185B1 (en) 2012-03-02 2016-01-13 Sareum Limited TYK2 kinase inhibitors
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5571810A (en) * 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
WO1998002430A1 (en) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP2004523476A (ja) * 2000-10-12 2004-08-05 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
US20040024047A1 (en) * 2001-10-12 2004-02-05 Callahan James F. Nf-kb inhibitors
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003029242A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation NF-λB INHIBITORS
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
DE60103132D1 (de) 2004-06-09
NO327741B1 (no) 2009-09-14
JP4812999B2 (ja) 2011-11-09
IL150482A (en) 2006-08-01
KR20030005183A (ko) 2003-01-17
GB0003154D0 (en) 2000-04-05
MXPA02007734A (es) 2002-10-11
CA2396824A1 (en) 2001-08-16
EP1261600A1 (en) 2002-12-04
DE60103132T2 (de) 2005-05-12
US20020107252A1 (en) 2002-08-08
US7358376B2 (en) 2008-04-15
US20090181962A1 (en) 2009-07-16
NO20023786D0 (no) 2002-08-09
IL150482A0 (en) 2002-12-01
JP2003522766A (ja) 2003-07-29
AU3070501A (en) 2001-08-20
WO2001058890A1 (en) 2001-08-16
ATE266019T1 (de) 2004-05-15
CN1425012A (zh) 2003-06-18
NO20023786L (no) 2002-09-23
CA2396824C (en) 2010-11-16
CN1243747C (zh) 2006-03-01
TR200401962T4 (tr) 2004-09-21
AU781047B2 (en) 2005-05-05
DK1261600T3 (da) 2004-08-16
EP1261600B1 (en) 2004-05-06
PT1261600E (pt) 2004-08-31
ZA200205300B (en) 2003-10-02
KR100738165B1 (ko) 2007-07-10
NZ519947A (en) 2004-05-28
ES2218376T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
BR0108143A (pt) Derivados heteroaromáticos de carboxamida e seu uso como inibidores da enzima ikk-2
CY1111543T1 (el) Νεες ενωσεις
NO20053810D0 (no) Thiofenkarboksamider som inhibitorer av enzymet IKK-2
MXPA04000755A (es) Nuevos compuestos.
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
DE60221537D1 (de) Pteridinon-derivate als modulatoren der chemokinrezeptor-aktivität
BR0208566A (pt) Derivados de beta-carbolina
BRPI0412862A (pt) derivados da nicotinamida úteis como inibidores de pde4
DE60130009D1 (de) Makrolide
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
SE9901079D0 (sv) Novel compounds
MXPA03003466A (es) Derivados de piranosido.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO OBSTACULO ADMINISTRATIVO E DEVOLVIDO 15 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/2004.

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.